AcouSort (ACOU) Q3 2024 earnings summary

Executive summary

• Expanded collaborations in flow cytometry, cell therapy, and quality control, including new partnerships with leading institutions and companies in Europe and North America.

• Participation in major industry events and conferences, such as Global Bio-India 2024 and ISCT Europe, to showcase technology and expand networks.

• Focused on commercialization through OEM partnerships and benchtop system placements, with intensified efforts to increase sales and external validations.

Financial highlights

• Q3 2024 net sales were TSEK 1,198, up from TSEK 1,121 in Q3 2023; total income for Q3 was TSEK 1,879, down from TSEK 2,160 year-over-year.

• Result before tax for Q3 2024 was TSEK -3,807, an improvement from TSEK -4,303 in Q3 2023.

• Earnings per share for Q3 2024 were SEK -0.25, compared to SEK -0.33 in Q3 2023.

• Cash and cash equivalents at September 30, 2024, were TSEK 9,538, compared to TSEK 6,550 a year earlier.

• Equity ratio improved to 64% from 53% year-over-year.

Outlook and guidance

• Confident in ability to continue planned activities into Q3 2025, supported by loan guarantees of SEK 4.5 million and current cash position.

• Strategy to increase OEM partnerships and benchtop system sales, with a focus on diagnostics, cell therapy, and flow cytometry markets.

• Plans to intensify commercial activities and external validations, especially for AcouTrap and AcouWash platforms.